LabStyle Innovations, Creator of Dario? Diabetes mHealth Solution, to Present at the See Thru Equity 3rd Annual Microcap Investor Conference - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
LabStyle Innovations, Creator of Dario? Diabetes mHealth Solution, to Present at the See Thru Equity 3rd Annual Microcap Investor Conference President and CEO Erez Raphael to address how mHealth can make life easier for people with diabetes and other chronic diseases


LabStyle Innovations, Creator of Dario™ Diabetes mHealth Solution, to Present at the See Thru Equity 3rd Annual Microcap Investor Conference

President and CEO Erez Raphael to address how mHealth can make life easier for people with diabetes and other chronic diseases

PR Newswire

CAESAREA, Israel, May 22, 2014 /PRNewswire/ --  LabStyle Innovations Corp . (OTCQB: DRIO), developer of the Dario™ Diabetes mHealth Solution today announced that its president and chief executive officer, Mr. Erez Raphael, will be presenting at the See Thru Equity 3rd Annual Microcap Investor Conference on Thursday, May 28, 2014 in New York City at Convene Grand Central at 101 Park Avenue at 41st Street. 

Mr. Raphael will discuss how mHealth solutions like Dario™ create the potential to make life easier for people with chronic diseases like diabetes all over the world.  The presentation is scheduled for 9:30 am. EDT and will be available via a live webcast. To access the webcast go to http://wsw.com/webcast/seethru7/drio A replay of the presentation will be available on LabStyle's website, http://mydario.investorroom.com , for 30 days following the presentation.

For more information or to register, please visit the conference website at www.seethruequity.com.

About LabStyle Innovations

LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario personalized Diabetes mHealth Solution.  Dario received CE mark certification in September 2013 and began a world rollout of the Dario mobile application in select countries in December 2013, and initial launches of the full Dario solution have commenced in Europe, Australia and New Zealand during 2014.  LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario Blood Glucose Monitoring System) in December 2013.  LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services, and in April 2014 LabStyle received a Notice of Allowance for a U.S. patent covering core functions of the Dario Blood Glucose Monitoring System.  For more information: www.mydario.com and http://mydario.investorroom.com.

Cautionary Note Regarding Forward-Looking Statements

This news release, the presentation referred to herein, and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. 

Dario™ and the Dario™ logo are trademarks owned by LabStyle Innovation Ltd.

© 2014 LabStyle Innovations Corp.  All rights reserved.

 

Contacts:


Press

Investor Relations



Brenda Zeitlin

LabStyle Innovations

Book and Company Inc.

1 212 490 9095

972 54 3304831

admin@bookeandco.com

Brenda@mydario.com


 

SOURCE LabStyle Innovations Corp.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here